Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?   

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clinical trial?



Answer from: Radiation Oncologist at Academic Institution